2.72
0.37%
0.01
After Hours:
2.72
Immuron Limited Adr stock is traded at $2.72, with a volume of 2,558.
It is up +0.37% in the last 24 hours and up +1.87% over the past month.
Immuron Ltd is a clinical-stage biopharmaceutical company focused on the development and commercialization of a novel class of immunomodulator polyclonal antibodies to treat liver diseases, infectious diseases and other immune-mediated diseases, such as colitis. The company's product, IMM-124E, is a proprietary immunomodulatory agent targeted at GI immune-mediated diseases including fatty liver diseases. The company functions in two segments namely, Research and Development and Hyperimmune products.
See More
Previous Close:
$2.71
Open:
$2.66
24h Volume:
2,558
Relative Volume:
0.41
Market Cap:
$15.50M
Revenue:
$2.35M
Net Income/Loss:
$-2.56M
P/E Ratio:
-6.1874
EPS:
-0.4396
Net Cash Flow:
-
1W Performance:
+9.90%
1M Performance:
+1.87%
6M Performance:
+3.42%
1Y Performance:
+37.37%
Immuron Limited Adr Stock (IMRN) Company Profile
Immuron Limited Adr Stock (IMRN) Latest News
IMRNImmuron Limited American Depositary Shares Latest Stock News & Market Updates - StockTitan
Immuron Plans Phase 2 Trial for IMM-529 following FDA review - Markets Insider
Immuron Plans Phase 2 Trial for IMM-529 following FDA review | Daily Guardian - Daily Guardian Canada
Immuron Plans Phase 2 Trial for IMM-529 following FDA review - GlobeNewswire
Immuron secures new US DoD research award - Investing.com
Immuron secures new US DoD research award - Investing.com India
Immuron secures new US DoD research award By Investing.com - Investing.com Australia
Immuron Announces New U.S. Department of Defense Research Award for Naval Medical Research Command and Walter Reed Army Institute of Research to advance Travelan® - GlobeNewswire Inc.
Presenting on the Emerging Growth Conference 73 Day 2 on July 18 Register Now - GlobeNewswire Inc.
Treasuries slip, dollar firm as markets grapple with US politics By Reuters - Investing.com
Curtiss Wright CEO Lynn M Bamford buys $10.2k in stock By Investing.com - Investing.com India
Immuron CEO to present at Sharewise investor event By Investing.com - Investing.com
Immuron to raise up to $2M as part of an ATM equity offering (NASDAQ:IMRN) - Seeking Alpha
Immuron secures around US$2 million in funding after lodging Form F-3 and ATM prospectus with US SEC By ... - Investing.com
Immuron requests pre-IND meeting for IMM-529 with FDA filing - Markets Insider
Immuron requests pre-IND meeting for IMM-529 with FDA filing | Daily Guardian - Daily Guardian Canada
Immuron requests pre-IND meeting for IMM-529 with FDA filing - GlobeNewswire
IMRNImmuron Limited Latest Stock News & Market Updates - StockTitan
Immuron requests pre-IND meeting for IMM-529 with FDA filing - Yahoo Finance
Immuron files pre-investigational new drug US FDA application for superbug fighting IMM-529 - Proactive Investors Australia
Immuron Surges On U.S. DoD Funding For Travelan Research - Yahoo Movies UK
Immuron CEO, Steven Lydeamore to present at the Emerging Growth Conference - GlobeNewswire Inc.
Immuron Board Changes - GlobeNewswire Inc.
U.S. stocks higher at close of trade; Dow Jones Industrial Average up 0.34% - MSN
Immuron Limited to Present at the Emerging Growth Conference - GlobeNewswire Inc.
Immuron Director Resignation - GlobeNewswire Inc.
Immuron to host Live Virtual Event - GlobeNewswire Inc.
Why Ascent Solar Technologies Shares Are Trading Lower By Around 50%? Here Are Other Stocks Moving In Wednesday's Mid-Day Session - Benzinga
Why PriceSmart Shares Are Trading Higher By Around 5%; Here Are 20 Stocks Moving Premarket - Benzinga
Immuron Travelan® sales continued strong growth - GlobeNewswire Inc.
Why PriceSmart Shares Are Trading Higher By Around 5%; Here Are 20 Stocks Moving Premarket - Markets Insider
U.S. shares higher at close of trade; Dow Jones Industrial Average up 0.34% - Investing.com India
Immuron stock surges after mid-stage data for Travelan - Seeking Alpha
Check Up: These 4 ASX healthcare stocks come with Strong Buy recommendations - Stockhead
Check Up: Immuron wins big in US and Europe on travellers’ diarrhoea drug - Stockhead
Check Up: As Alzheimer’s grabs the spotlight, these ASX biotech stocks also impressed - Stockhead
45 Stocks Moving in Tuesday's Pre-Market SessionArbutus Biopharma (NASDAQ:ABUS), ACADIA Pharmaceutical - Benzinga
36 Stocks Moving in Monday's Pre-Market Session - Benzinga
The Daily Biotech Pulse: Sanofi, Regeneron Finalize Praluent Restructuring, Natus Pre-Announces Q1 Shortf - Benzinga
58 Biggest Movers From YesterdayArbutus Biopharma (NASDAQ:ABUS), Acer Therapeutics Inc (OTC:ACER) - Benzinga
IMMURON LIMITED - ShareCafe
Immuron Limited Trade Ideas — NASDAQ:IMRN - TradingView
29 Stocks Moving In Wednesday's Mid-Day SessionBabcock & Wilcox (NYSE:BW), AstroNova (NASDAQ:ALOT) - Benzinga
35 Stocks Moving In Tuesday's Mid-Day SessionAyala Pharmaceuticals (OTC:ADXS) - Benzinga
Immuron Limited Adr Stock (IMRN) Financials Data
Revenue
Net Income
Cash Flow
EPS
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):